CEACAM5 and neoplasm: Currently, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9 are used as tumor markers in clinical practice for the diagnosis, prognosis, and monitoring of CRC patients [46,47,48,49,50].